Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. Cancer J Clin 71:7–33. https://doi.org/10.3322/caac.21654

Article  Google Scholar 

Naidoo J, Nishino M, Patel SP, Shankar B, Rekhtman N, Illei P, Camus P (2020) Immune-related pneumonitis after chemoradiotherapy and subsequent immune checkpoint blockade in unresectable stage III non-small-cell Lung Cancer. Clin Lung Cancer 21(5):e435–e444. https://doi.org/10.1016/j.cllc.2020.02.025

Article  CAS  PubMed  Google Scholar 

Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287. https://doi.org/10.1038/nrc.2016.36

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al (2010) Improved survival with ipilimumab in patients with metastatic Melanoma. N Engl J Med 363:711–723. https://doi.org/10.1056/NEJMoa1003466

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372:2521–2532. https://doi.org/10.1056/NEJMoa1503093

Article  CAS  PubMed  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF et al (2017) Overall survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 377:1345–1356. https://doi.org/10.1056/NEJMoa1709684

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S et al (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-cell Lung Cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774

Article  CAS  PubMed  Google Scholar 

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17:956–965. https://doi.org/10.1016/s1470-2045(16)30066-3

Article  CAS  PubMed  Google Scholar 

Feng Y, Wang Y, Guo K, Feng J, Shao C, Pan M, Ding P, Liu H, Duan H, Lu D et al (2022) The value of WNT5A as prognostic and immunological biomarker in pan-cancer. Annals of Translational Medicine 10:466. https://doi.org/10.21037/atm-22-1317

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in Cancer Immunotherapy. Mol Cancer Ther 14:847–856. https://doi.org/10.1158/1535-7163.mct-14-0983

Bai X, Wu DH, Ma SC, Wang J, Tang XR, Kang S, Fu QJ, Cao CH, Luo HS, Chen YH et al (2020) Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study. Journal for immunotherapy of cancer 8. https://doi.org/10.1136/jitc-2019-000381

Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R (2021) The challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell 39:154–173. https://doi.org/10.1016/j.ccell.2020.10.001

Article  CAS  PubMed  Google Scholar 

Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, Penault-Llorca F (2019) Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO open 4:e000442. https://doi.org/10.1136/esmoopen-2018-000442

Article  PubMed  PubMed Central  Google Scholar 

Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202–206. https://doi.org/10.1038/s41588-018-0312-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Subbiah V, Solit D, Chan T, Kurzrock R (2020) The FDA approval of pembrolizumab for adult and pediatric patients with Tumor mutational burden (TMB) ≥ 10: a decision centered on empowering patients and their physicians. Ann Oncol 31:1115–1118

Article  CAS  PubMed  Google Scholar 

Strickler JH, Hanks BA, Khasraw M (2021) Tumor Mutational Burden as a predictor of Immunotherapy Response: is more always better? Clinical cancer research. Official J Am Association Cancer Res 27:1236–1241. https://doi.org/10.1158/1078-0432.ccr-20-3054

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A et al (2018) Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 50:1271–1281. https://doi.org/10.1038/s41588-018-0200-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu S, Liu D, Chang T, Wen X, Ma S, Sun G, Wang L, Chen S, Xu Y, Zhang H (2022) Cuproptosis-Associated lncRNA establishes New Prognostic Profile and predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Front Genet 13:938259. https://doi.org/10.3389/fgene.2022.938259

Article  CAS  PubMed  PubMed Central  Google Scholar 

Formica V, Sera F, Cremolini C, Riondino S, Morelli C, Arkenau HT, Roselli M (2022) KRAS and BRAF mutations in stage II and III Colon Cancer: a systematic review and Meta-analysis. J Natl Cancer Inst 114:517–527. https://doi.org/10.1093/jnci/djab190

Article  CAS  PubMed  Google Scholar 

Liu K, Wang JF, Zhan Y, Kong DL, Wang C (2021) Prognosis model of Colorectal cancer patients based on NOTCH3, KMT2C, and CREBBP mutations. J Gastrointest Oncol 12:79–88. https://doi.org/10.21037/jgo-21-28

Article  PubMed  PubMed Central  Google Scholar 

Jiao S, Zhang X, Wang D, Fu H, Xia Q (2022) Genetic alteration and their significance on clinical events in small cell Lung Cancer. Cancer Manage Res 14:1493–1505. https://doi.org/10.2147/cmar.s356037

Article  Google Scholar